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 The Federal 340B Drug Pricing 
Program 
– provides discounted drug prices 
to hospitals and other health care  
organizations that serve 
low-income patients 
– purpose of the 340B program has been to use its 
savings incentives to help safety net providers 
increase their amount of patient services 
 individuals with low income and/or uninsured were 
the main targeted patients 
 offers discounts to hospitals for the purchase of 
outpatient drugs regardless of the patient's’ ability 
to pay
Introduction
 The Federal 340B Drug Pricing 
Program 
– between 2010 and 2015, the 340B 
program more than doubled in size, 
and between 2013 and 2015 alone it 
expanded by 66%
– The program is forecasted to exceed $23 billion 
in total sales by 2021, with growth largely driven 
by expanded utilization at existing 340B-covered 
entities through contract pharmacy programs 
and from practice acquisitions, physician 
practice affiliations, and patient referrals
Introduction
340B Audit Compliance
 Since 2012, HRSA has conducted audits of 
covered entities to assess whether they 
complied with statutory prohibitions against 
diversion and duplicate discounts 
 The latest audit results have revealed 
noncompliance rates that exceeded 69% and 
have reflected challenges in covered entities’ 
ability to comply with statutory requirements 
and HRSA’s administration of the 340B 
program 
340B and Providers: Hospitals
 The 340B program has increased profits for 
hospitals through contract pharmacies 
because they have still received the same 
reimbursement but acquired drugs at a lower 
rate
 Although drugs dispensed to hospital 
inpatients are supposed to be ineligible for 
purchase through the 340B program, the 
tracking mechanism regarding how and for 
how much these drugs were purchased, and to 
whom and at what price they were dispensed, 
is simply inadequate
340B and Providers: Hospitals
 Because 340B prescriptions purchased from 
contract pharmacies cannot be identified at the 
time of payment, third-party payers are forced 
to reimburse 340B and non-340B outpatient 
prescriptions at the same rate
 Therefore, a 340B entity can “arbitrage” the 
system by buying drugs at the 340B rate and 
charging for these same drugs at the non-340B 
rate
340B and Hospitals
 Medicare and commercial payers can’t identify 
the extent of the “excess”, because providers 
are not required to report the payer for 340B 
prescriptions 
– Duke University Hospital profited $282 
million in 5 years through outpatient 
departments and other affiliated clinics 
from their participation in 340B
– Duke University Hospital’s reply: “It is very difficult ... to 
accurately calculate gross or net revenues from 
outpatient pharmaceuticals due to many factors, including 
the complicated reimbursement models for 
pharmaceuticals”
– In any event, only 5% of the patients treated at Duke 
University Hospital were uninsured, so the other 95% had 
some sort of insurance coverage; i.e., Medicare, Medicaid, 
or private insurance
340B and Providers: Practitioners
 Because physicians in private practice are 
ineligible to purchase drugs for their private 
patients through the 340B program, they have 
found it increasingly difficult to compete with 
hospital-based oncology practices, and 
consequently many are selling their practices to 
hospitals which do to participate in the 340B 
Program
 More than 1,200 independent oncology clinics 
have either closed or been acquired by 
hospitals in the last decade
340B and Providers: Practitioners
 a single practicing oncologist whose practice 
was acquired by a 340B hospital could gain an 
additional $1 million profit by purchasing 
oncology drugs at a discount through the 
hospital’s participation in a 340B program
 the acquisition of oncology practices by 
hospitals participating in the 340B Program 
has accelerated
– in 2012 and 2013, 75% of community oncology 
practices were purchased by hospitals with 340B 
programs
– the rate of closing of community oncology practices 
having increased 87% per month
340B and Hospital Accountability
 There is no requirement that hospitals spend 
any savings from the 340B program directly on 
patients, let alone on low-income patients, or 
that hospitals report to anyone, public or 
private, how the savings are spent
 Desai and McWilliams (2018) found “no 
evidence of hospitals using the surplus 
monetary resources generated from 
administering discounted drugs to invest in 
safety-net providers, provide more inpatient 
care to low-income patients, or enhance care for 
low-income groups in ways that would reduce 
mortality.”
Recent Developments
 In May, the Trump administration asked 340B 
stakeholders to weigh in on measures that 
have been floated in Congress, including a 
"patient definition" that would specify who 
qualifies for the drug discount, and moving 
340B regulatory authority to HHS
CONCLUSIONS
 The federal 340B Drug Pricing Program has 
continued to grow since being signed into law
 Although it was originally designed to serve 
the needs of low-income Americans, it appears 
to have morphed into a mechanism for 
healthcare providers to enrich their bottom 
lines regardless of the income level of the 
population they serve
 More comprehensive data obtained using a 
better cost accounting system for providers 
and analysis by impartial parties will be 
necessary if the situation is to be resolved
The law of unintended consequences holds that almost 
all human actions have at least one unintended 
consequence.  Unintended consequences are a 
common phenomenon, due to the complexity of the 
world and human over-confidence. 
